$BLUE
bluebird bio, Inc. Stock $blue

$blue Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514306702 Filed on August 12, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$6.365M	$6.335M	$6.334M
YoY Change	-0.31%	0.02%	7351.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.600M	$5.700M	$3.300M
YoY Change	73.68%	72.73%	153.85%
% of Gross Profit
Research & Development	$16.65M	$13.93M	$7.247M
YoY Change	91.24%	92.23%	116.07%
% of Gross Profit
Depreciation & Amortization	$1.540M	$540.0K	$160.0K
YoY Change	396.77%	237.5%	128.57%
% of Gross Profit
Operating Expenses	$16.65M	$19.67M	$7.247M
YoY Change	91.24%	171.41%	116.07%
Operating Profit	-$17.01M	-$13.33M	-$4.194M
YoY Change	176.27%	217.93%	-8.83%
Interest Expense	-$100.0K		-$400.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$20.00K	$11.00K	-$389.0K
YoY Change	-145.45%	-102.83%	-1151.35%
Pretax Income	-$17.03M	-$13.32M	-$4.583M
YoY Change	178.59%	190.7%	-0.37%
Income Tax	$0.00	-$11.80M	$0.00
% Of Pretax Income
Net Earnings	-$17.03M	-$1.526M	-$4.583M
YoY Change	178.59%	-66.7%	0.44%
Net Earnings / Revenue	-267.56%	-24.09%	-72.36%
Basic Earnings Per Share
Diluted Earnings Per Share	-$605.0K	-$61.22K	-$2.091M
COMMON SHARES
Basic Shares Outstanding	28.60M shares	24.51M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$215.4M	$175.7M	$228.8M
YoY Change	-0.65%	-23.21%
Cash & Equivalents	$89.60M	$175.7M	$228.8M
Short-Term Investments	$125.8M
Other Short-Term Assets	$7.900M	$7.200M	$1.700M
YoY Change	68.09%	323.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$223.3M	$182.9M	$230.5M
YoY Change	0.84%	-20.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.98M	$12.86M	$2.515M
YoY Change	177.78%	411.21%
Goodwill	$13.13M	$13.13M
YoY Change
Intangibles	$29.16M	$30.10M
YoY Change
Long-Term Investments	$48.40M
YoY Change
Other Assets	$1.162M	$1.700M	$1.500M
YoY Change	-17.0%	13.33%
Total Long-Term Assets	$106.9M	$57.75M	$4.018M
YoY Change	1472.82%	1337.36%
TOTAL ASSETS
Total Short-Term Assets	$223.3M	$182.9M	$230.5M
Total Long-Term Assets	$106.9M	$57.75M	$4.018M
Total Assets	$330.2M	$240.6M	$234.5M
YoY Change	44.66%	2.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.641M	$2.586M	$1.609M
YoY Change	218.27%	60.72%
Accrued Expenses	$9.700M	$11.70M	$3.400M
YoY Change	94.0%	244.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$38.52M	$39.55M	$30.36M
YoY Change	22.34%	30.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$323.0K	$352.0K	$42.90M
YoY Change	-99.17%	-99.18%
Total Long-Term Liabilities	$323.0K	$352.0K	$42.90M
YoY Change	-99.17%	-99.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.52M	$39.55M	$30.36M
Total Long-Term Liabilities	$323.0K	$352.0K	$42.90M
Total Liabilities	$68.30M	$74.87M	$73.27M
YoY Change	-3.2%	2.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.8M	-$110.8M	-$84.48M
YoY Change	41.11%	31.17%
Common Stock	$287.0K	$251.0K	$236.0K
YoY Change	21.61%	6.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$261.9M	$165.8M	$161.3M
YoY Change
Total Liabilities & Shareholders Equity	$330.2M	$240.6M	$234.5M
YoY Change	44.66%	2.59%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$17.03M	-$1.526M	-$4.583M
YoY Change	178.59%	-66.7%	0.44%
Depreciation, Depletion And Amortization	$1.540M	$540.0K	$160.0K
YoY Change	396.77%	237.5%	128.57%
Cash From Operating Activities	-$20.77M	-$11.33M	-$8.250M
YoY Change	134.42%	37.33%	106.77%
INVESTING ACTIVITIES
Capital Expenditures	-$1.770M	-$2.010M	-$460.0K
YoY Change	-16.11%	336.96%	155.56%
Acquisitions
YoY Change
Other Investing Activities	-$173.8M	-$4.670M	-$1.250M
YoY Change	-173920.0%	273.6%
Cash From Investing Activities	-$175.6M	-$6.690M	-$1.710M
YoY Change	8635.32%	291.23%	850.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	110.2M	1.230M	107.0M
YoY Change	-9442.37%	-98.85%	1069600.0%
NET CHANGE
Cash From Operating Activities	-20.77M	-11.33M	-8.250M
Cash From Investing Activities	-175.6M	-6.690M	-1.710M
Cash From Financing Activities	110.2M	1.230M	107.0M
Net Change In Cash	-86.11M	-16.79M	97.01M
YoY Change	614.61%	-117.31%	-2431.97%
FREE CASH FLOW
Cash From Operating Activities	-$20.77M	-$11.33M	-$8.250M
Capital Expenditures	-$1.770M	-$2.010M	-$460.0K
Free Cash Flow	-$19.00M	-$9.320M	-$7.790M
YoY Change	181.48%	19.64%	104.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	blue	Additional Lease Rent Payable AdditionalLeaseRentPayable	47000
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28595796	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228847000
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25077000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1383000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25077000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.59
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4112000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	806000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.64
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	338000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4058000	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.61
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276315000
CY2014Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	6550000
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2586000
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	39547000
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	352000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	165756000
CY2014Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6550000
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110810000
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25291000
CY2014Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8056000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	251000
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240622000
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3106000
CY2014Q2	us-gaap	Liabilities Liabilities	74866000
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	17708000
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	13167000
CY2014Q2	us-gaap	Assets Current AssetsCurrent	182869000
CY2014Q2	us-gaap	Goodwill Goodwill	13128000
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30100000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3763000
CY2014Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	175710000
CY2014Q2	us-gaap	Assets Assets	240622000
CY2014Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	175710000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175710000
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	30100000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3763000
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4053000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3763000
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	21288000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3763000
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	3106000
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12857000
CY2014Q2	blue	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	11670000
CY2014Q2	blue	Finite Lived Intangible Assets Amortization Expense Year One FiniteLivedIntangibleAssetsAmortizationExpenseYearOne	1881000
CY2014Q2	blue	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6097000
CY2014Q2	blue	Restricted Cash And Other Non Current Assets RestrictedCashAndOtherNonCurrentAssets	1668000
CY2014Q2	blue	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Held By Former Employees ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesHeldByFormerEmployees	123000	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67011000
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23940000	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	338000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23940000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.21
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3958000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	250103000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4359000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34874000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	208000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	151667000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98675000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25340000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6740000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	239000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	224390000
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	693000
CY2013Q4	us-gaap	Liabilities Liabilities	72723000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	30208000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Assets Current AssetsCurrent	211987000
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	206279000
CY2013Q4	us-gaap	Assets Assets	224390000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206279000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5015000
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	693000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10920000
CY2013Q4	blue	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	5175000
CY2013Q4	blue	Restricted Cash And Other Non Current Assets RestrictedCashAndOtherNonCurrentAssets	1483000
CY2013Q2	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P9Y
CY2013Q2	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2013Q2	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	209000
CY2013Q2	blue	Letter Of Credit Related With New Lease Agreement LetterOfCreditRelatedWithNewLeaseAgreement	1253000
CY2013Q2	blue	Rent Abatement Credits RentAbatementCredits	209000
CY2013Q2	blue	Area Of Leased Space AreaOfLeasedSpace	43600	sqft
CY2013Q2	blue	Landlord Contribution For Leasehold Improvements LandlordContributionForLeaseholdImprovements	6538000
CY2014Q2	blue	Additional Lease Space Agreement AdditionalLeaseSpaceAgreement	9869	sqft
CY2014Q2	blue	Landlord Contribution For Leasehold Improvements LandlordContributionForLeaseholdImprovements	1234000
CY2014Q2	blue	Lease Amendment Effective Month And Year LeaseAmendmentEffectiveMonthAndYear	2014-09
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1244000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	57765000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.94
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4440000	shares
	us-gaap	Revenues Revenues	7461000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	906000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11127000
	us-gaap	Contracts Revenue ContractsRevenue	7291000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11127000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	281000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-452000
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	655000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10675000
	us-gaap	Net Income Loss NetIncomeLoss	-11127000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1265000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1253000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	170000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	617000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	440000
	us-gaap	Costs And Expenses CostsAndExpenses	18136000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5605000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	106589000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	67539000
	us-gaap	Share Based Compensation ShareBasedCompensation	2318000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	304000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	161836000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2518000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1416000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	106180000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12531000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	65000
	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	344000
	blue	Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	1259000
	blue	Conversion Of Convertible Preferred Stock To Common Stock Upon Ipo ConversionOfConvertiblePreferredStockToCommonStockUponIpo	119841000
	blue	Increase Decrease In Deferred Rent Payable IncreaseDecreaseInDeferredRentPayable	-6000
	dei	Entity Registrant Name EntityRegistrantName	bluebird bio, Inc.
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001293971
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Description of the business</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company was formed to develop, manufacture and market therapies to safely and effectively deliver genes useful in the treatment of serious human diseases. Since its inception, the Company has devoted substantially all of its resources to its development efforts relating to its product candidates, including activities to manufacture product in compliance with good manufacturing practices (“GMP”), conduct clinical studies of its product candidates, provide general and administrative support for these operations and protect its intellectual property.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> On June 30, 2014, the Company acquired all of the outstanding capital stock of Precision Genome Engineering, Inc. (“Pregenen”) and in connection therewith, obtained the rights to Pregenen’s gene editing and cell signaling technology. See Note 6, “Business combinations,” for additional information.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24312000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.66
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23258000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	937000	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2015-03-31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	92000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	691000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	14.98
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4571000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: acquisition-date fair value and subsequent fair value estimates used to assess impairment of long-lived assets, including goodwill and intangible assets, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p> </div>
	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Three months or less
	us-gaap	Revenues Revenues	12670000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-854000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12135000
	us-gaap	Contracts Revenue ContractsRevenue	12500000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23932000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	344000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4673000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24001000
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11797000
	us-gaap	Net Income Loss NetIncomeLoss	-12135000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4534000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	170000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7674000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	168000
	us-gaap	Costs And Expenses CostsAndExpenses	36671000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11277000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1864000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1896000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	643000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12670000
	us-gaap	Share Based Compensation ShareBasedCompensation	4843000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1017000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-30569000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-9207000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2702000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25394000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1896000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11797000
	blue	Deferred Stock Offering Costs Included In Accounts Payable And Accrued Liabilities DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities	45000
	blue	Increase Decrease In Deferred Rent Payable IncreaseDecreaseInDeferredRentPayable	1490000
	blue	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
	blue	Receivable For Stock Option Exercise ReceivableForStockOptionExercise	75000
	blue	Class Of Warrant Or Right Cancelled Or Expired In Period ClassOfWarrantOrRightCancelledOrExpiredInPeriod	0	shares
	blue	Number Of New Employees Hired For Additional Headcount NumberOfNewEmployeesHiredForAdditionalHeadcount	15	Employees
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	960000	shares
CY2014Q1	blue	Tax Incentive Program Tax Incentive Awarded TaxIncentiveProgramTaxIncentiveAwarded	306000
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2151000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.13
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4440000	shares
CY2013Q2	us-gaap	Revenues Revenues	6334000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4583000
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	6249000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4583000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-389000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4194000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-4583000
CY2013Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	85000
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	10528000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3281000
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1657000
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7247000
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24474000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4571000	shares
CY2014Q2	us-gaap	Revenues Revenues	6335000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1526000
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	6250000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13323000
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13334000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1526000
CY2014Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	85000
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	19669000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5738000
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2351000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13931000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11797000
CY2014Q2	blue	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
CY2014Q2	blue	Class Of Warrant Or Right Cancelled Or Expired In Period ClassOfWarrantOrRightCancelledOrExpiredInPeriod	0	shares

Files In Submission

Name	View Source	Status
blue-20140630_pre.xml	Edgar Link	unprocessable
0001193125-14-306702-index-headers.html	Edgar Link	pending
0001193125-14-306702-index.html	Edgar Link	pending
0001193125-14-306702.txt	Edgar Link	pending
0001193125-14-306702-xbrl.zip	Edgar Link	pending
blue-20140630.xml	Edgar Link	completed
blue-20140630.xsd	Edgar Link	pending
blue-20140630_cal.xml	Edgar Link	unprocessable
blue-20140630_def.xml	Edgar Link	unprocessable
blue-20140630_lab.xml	Edgar Link	unprocessable
d755159d10q.htm	Edgar Link	pending
d755159dex1024.htm	Edgar Link	pending
d755159dex211.htm	Edgar Link	pending
d755159dex311.htm	Edgar Link	pending
d755159dex312.htm	Edgar Link	pending
d755159dex321.htm	Edgar Link	pending
d755159dex46.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLUE
bluebird bio, Inc. Stock $blue

2014 Q3 Form 10-Q Financial Statement

#000119312514306702 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE bluebird bio, Inc. Stock $blue

2014 Q3 Form 10-Q Financial Statement

#000119312514306702 Filed on August 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE
bluebird bio, Inc. Stock $blue